Related references
Note: Only part of the references are listed.A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Edward Fox et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab
Chiara Rosa Mancinelli et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
Maria P. Sormani et al.
ANNALS OF NEUROLOGY (2021)
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Anthony T. Reder et al.
CNS DRUGS (2021)
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
Diego Centonze et al.
JOURNAL OF NEUROLOGY (2021)
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
Amber Salter et al.
JAMA NEUROLOGY (2021)
Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
Arpan Patel et al.
JAMA NEUROLOGY (2021)
B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies
Maria T. Cencioni et al.
NATURE REVIEWS NEUROLOGY (2021)
Rituximab treatment for multiple sclerosis
Benjamin V. Ineichen et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience
Chiara Zecca et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Peter Alping et al.
ANNALS OF NEUROLOGY (2020)
Ocrelizumab initiation in patients with MS A multicenter observational study
Erik Ellwardt et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Inhibition of Bruton's tyrosine kinase as a novel therapeutic approach in multiple sclerosis
Sebastian Torke et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension
Stephen L. Hauser et al.
NEUROLOGY (2020)
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis The VELOCE study
Amit Bar-Or et al.
NEUROLOGY (2020)
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis
Edgar Carnero Contentti et al.
EXPERT OPINION ON EMERGING DRUGS (2020)
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis
David Baker et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Jerry S. Wolinsky et al.
LANCET NEUROLOGY (2020)
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
Mark A. Agius et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
Mark A. Agius et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Efficacy of rituximab in refractory RRMS
Pierre Durozard et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Efficacy of rituximab in refractory RRMS
Pierre Durozard et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
Benjamin Turner et al.
JOURNAL OF NEUROLOGY (2019)
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Xavier Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement
Pavan Bhargava et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis
Justin M. Honce et al.
NEUROLOGY (2019)
Inflammatory intrathecal profiles and cortical damage in multiple sclerosis
Roberta Magliozzi et al.
ANNALS OF NEUROLOGY (2018)
The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+T lymphocytes and B cells
Joana Machado-Santos et al.
BRAIN (2018)
New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies
Saskia Meyer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
Chengyuan Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis
Hanane Touil et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study
Carmen Alcala et al.
JOURNAL OF NEUROLOGY (2018)
Reassessing B cell contributions in multiple sclerosis
Rui Li et al.
NATURE IMMUNOLOGY (2018)
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study
Amit Bar-Or et al.
NEUROLOGY (2018)
Multiple Sclerosis: Mechanisms and Immunotherapy
Clare Baecher-Allan et al.
NEURON (2018)
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
Mathias Granqvist et al.
JAMA NEUROLOGY (2018)
Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study
Bassem I. Yamout et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
Jeffrey M. Gelfand et al.
NEUROTHERAPEUTICS (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Peter Alping et al.
ANNALS OF NEUROLOGY (2016)
Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab
Pierre de Flon et al.
NEUROLOGY (2016)
Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy
Jonatan Salzer et al.
NEUROLOGY (2016)
Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis
Rui Li et al.
FRONTIERS IN IMMUNOLOGY (2016)
Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies
Ding Chen et al.
JOURNAL OF CLINICAL MEDICINE (2016)
Progressive multiple sclerosis 1 Pathological mechanisms in progressive multiple sclerosis
Don H. Mahad et al.
LANCET NEUROLOGY (2015)
Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy
Rui Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Immunopathology of multiple sclerosis
Calliope A. Dendrou et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study
Adipong Brickshawana et al.
LANCET NEUROLOGY (2014)
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
Per S. Sorensen et al.
NEUROLOGY (2014)
Rituximab for the treatment of rheumatoid arthritis: an update
Chi Chiu Mok
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging
Fabricio Montalvao et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
B-Cell Enrichment and Epstein-Barr Virus Infection in Inflammatory Cortical Lesions in Secondary Progressive Multiple Sclerosis
Roberta Magliozzi et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2013)
Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica
Chun-Sheng Yang et al.
NEUROLOGY (2013)
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells
Tom A. Barr et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis
Rajneesh Srivastava et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
Inflammatory Cortical Demyelination in Early Multiple Sclerosis
Claudia F. Lucchinetti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Abnormal B-Cell Cytokine Responses A Trigger of T-Cell Mediated Disease in MS?
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2010)
A Gradient of Neuronal Loss and Meningeal Inflammation in Multiple Sclerosis
Roberta Magliozzi et al.
ANNALS OF NEUROLOGY (2010)
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis - A 52-week phase II trial
R. T. Naismith et al.
NEUROLOGY (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Josa M. Frischer et al.
BRAIN (2009)
CD19: a promising B cell target for rheumatoid arthritis
Thomas F. Tedder
NATURE REVIEWS RHEUMATOLOGY (2009)
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
Amit Bar-Or et al.
ANNALS OF NEUROLOGY (2008)
Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis
Birgit Obermeier et al.
NATURE MEDICINE (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The immunology of multiple sclerosis
Amit Bar-Or
SEMINARS IN NEUROLOGY (2008)
Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis
Martin Duddy et al.
JOURNAL OF IMMUNOLOGY (2007)
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
Roberta Magliozzi et al.
BRAIN (2007)
Lack of association between antimyelin antibodies and progression to multiple sclerosis
Jens Kuhle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation
E Meinl et al.
ANNALS OF NEUROLOGY (2006)
B cells as antigen presenting cells
D Rodríguez-Pinto
CELLULAR IMMUNOLOGY (2005)
Is inflammation important in early PPMS? a longitudinal MRI study
GT Ingle et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2005)
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis
S Cepok et al.
BRAIN (2005)
Share Paper
